New xenograft-based dressing might hit the market by summer

02/21/2012 | MedCityNews.com

Harbor Medtech is preparing to submit a request that the FDA approve its NeuvoCell wound dressing based on porcine tissue. NeuvoCell will be less expensive than similar products already on the market, requires applications only once or twice instead of every seven to 10 days, and will be appropriate to treat diabetic foot ulcers, pressure ulcers and burns, founder Jerry Mezger said.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC